CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Dentsply Sirona Q3 revenue misses estimates as dental segment sales decline

By Reuters News


Overview

  • Dental products maker's Q3 revenue fell 7.6% yr/yr, missing analyst expectations

  • Adjusted EPS for Q3 dropped 29% yr/yr

  • Results included a $39 mln one-time inventory accounting benefit, while Wellspect Healthcare posted record quarterly sales


Outlook

  • Dentsply Sirona updates 2026 net sales outlook to about $3.5 bln

  • Company expects 2026 adjusted EPS of $1.20-$1.30, excluding a $0.17 one-time tariff refund benefit


Result Drivers

  • WELLSPECT HEALTHCARE - Co achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth

  • INDUSTRY CONDITIONS - Co said challenging industry-wide conditions weighed on results, per CEO Dan Scavilla

  • BROAD-BASED SALES DECLINE - Constant-currency sales fell 7%, with declines across Connected Technology, Essential Dental and Orthodontic and Implant Solutions


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$836 mln

$862 mln (14 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for DENTSPLY SIRONA Inc. is $12.00, about 12.7% above its November 4 closing price of $10.65

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 4 - Envista Q3 sales rise 3.2%, slightly beat estimates

  • Nov 4 - Netherlands' Qiagen Q3 sales, adjusted EPS top outlook; suspends 2026 guidance

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.